SARS-CoV-2: Difference between revisions

From IDWiki
()
No edit summary
Line 26: Line 26:


*Incubation period [[Usual incubation period::4 to 5 days]] (range [[Incubation period::2 to 11 days]]), possibly as long as 14 days in some cases
*Incubation period [[Usual incubation period::4 to 5 days]] (range [[Incubation period::2 to 11 days]]), possibly as long as 14 days in some cases
*Main presenting symptoms were fever and cough, followed by myalgia, fatigue, headache, dyspnea
*Main presenting symptoms were [[fever]] and [[cough]], followed by [[myalgia]], [[fatigue]], [[headache]], [[dyspnea]]
*Other symptoms include dyspnea, rhinorrhea, vomiting, diarrhea, anosmia/hyposmia
*Other symptoms include [[dyspnea]], [[rhinorrhea]], [[vomiting]], [[diarrhea]], [[anosmia]]/[[hyposmia]]
*Lymphopenia is common, as is hypoalbuminemia, elevated D-dimer, CRP, LDH, AST/ALT
*[[Lymphopenia]] is common, as is hypoalbuminemia, elevated D-dimer, CRP, LDH, AST/ALT
*Viral load detectable before symptom onset and peaks around the time of symptom onset
*Viral load detectable before symptom onset and peaks around the time of symptom onset

=== Pregnancy ===

* Please refer to [https://doi.org/10.1136/bmj.m3320 a living systematic review on the topic]


===Complications===
===Complications===
Line 41: Line 45:


*PCR from NP swab
*PCR from NP swab
**Highest sensitivity within 5 days of symptom onset, with decreasing sensitivity as the disease enters the immune-mediated phase
**May be positive long after no longer infectious
**May be positive long after no longer infectious



Revision as of 23:49, 13 September 2020

Background

Microbiology

  • Coronavirus related to SARS-CoV
  • Virion consists of:
    • Spike glycoprotein (S)
    • Membrane protein (M)
    • Nucleocapsid protein (N)
    • Hemagglutinin esterase (He)
    • Envelope protein (E)

Epidemiology

  • First cases detected Dec 2019 related to likely exposure in wet market in Wuhan, Hubei, China, and declared a pandemic in 2020
  • Secondary household attack rate of 12-17%

Risk Factors for Mortality

Clinical Manifestations

Pregnancy

Complications

Diagnosis

  • PCR from NP swab
    • Highest sensitivity within 5 days of symptom onset, with decreasing sensitivity as the disease enters the immune-mediated phase
    • May be positive long after no longer infectious

Management

  • For patients no requiring supplemental oxygen, the focus is on supportive care
  • For patients requiring supplemental oxygen:
    • Dexamethasone 6 mg PO/IV daily for 10 days, which has a mortality benefit
    • Remdesivir 200 mg PO once on day one followed by 100 mg PO daily for 5-10 days, which has not been shown to have a mortality benefit
  • Avoid hydroxychloroquine/chloroquine, lopinavir-ritonavir
  • Other investigational therapeutics include tocilizumab

Further Reading